Not yet in sequence: Clinical, technical, ethical questions linger over personal genomics.

Center for Integration of Research on Genetics and Ethics, Stanford University School of Medicine, Palo Alto, Calif., USA.
Modern healthcare 11/2010; 40(47):24.
Source: PubMed
5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The rapid emergence of whole-genome and whole-exome sequencing of research participants has helped to revive the debate about whether genetic and other 'omic' data should be returned to research participants, and if so, which data, under what circumstances and by whom. While partial disclosure of such data has been justified in cases where participants' lives and health are threatened, full disclosure appears to remain beyond the pale for most researchers and bioethicists. I argue that it should not be and that the objections to full disclosure short-sightedly favor near-term considerations over long-term benefits. Return of genomic data to those who want it, even if a difficult undertaking and even if the meaning of the data is unclear, engages participants in science and the research enterprise, and positions them to be better stewards of their own health and wellbeing.
    Personalized Medicine 11/2011; 8(6):651-657. DOI:10.2217/pme.11.62 · 1.34 Impact Factor